Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 14Breast Neoplasms 11Prostatic Neoplasms 9Obesity 7Insulin Resistance 6Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Colorectal Neoplasms 4Motor Activity 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Menstruation Disturbances 2Lymphoma, Large B-Cell, Diffuse 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Diabetes Mellitus 2Weight Loss 1Urothelial Cancer 1Thyroid Diseases 1Thoracic Neoplasms 1Smoldering Multiple Myeloma 1Rectal Neoplasms 1Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Overweight 1Ovarian, Fallopian Tube, and Primary Peritoneal Cancer 1Non-alcoholic Fatty Liver Disease 1

Interventions

Lenalidomide 8Dexamethasone 6Calcium Dobesilate 6Melphalan 3elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Peripheral Blood Stem Cell Transplantation 2Bortezomib 2pomalidomide 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1Watchful Waiting 1Urination 1Transplantation, Autologous 1Stem Cell Transplantation 1Receptors, Interleukin-6 1Observation 1Nivolumab 1Metformin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1IPH-2101 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoldering Multiple Myeloma × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡